Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20898548 | 0.84 | LRRK2 (0.45) | LRRK2MMP2ADAMTS5OGACYP17A1 | |
| SCHEMBL20905522 | 0.76 | PRCP (0.42) | LRRK2OGAGPR119CYP2C19PRCP | |
| SCHEMBL83918 | 0.73 | MMP2 (0.41) | LRRK2MMP2ADAMTS5OGACYP17A1 | |
| SCHEMBL25142073 | 0.67 | HRH4 (0.43) | OGACYP17A1 | |
| SCHEMBL31614501 | 0.66 | OGA (0.41) | LRRK2OGACYP17A1GPR119CYP2C19 | |
| SCHEMBL16382029 | 0.66 | OGA (0.39) | MMP2ADAMTS5OGACYP17A1CYP2C19 | |
| SCHEMBL22796061 | 0.65 | MAP4K4 (0.49) | LRRK2PRCP | |
| SCHEMBL5025356 | 0.65 | ADORA2A (0.45) | MMP2ADAMTS5 | |
| SCHEMBL20898486 | 0.65 | PRCP (0.54) | LRRK2PRCP | |
| SCHEMBL20898487 | 0.65 | PRCP (0.54) | LRRK2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, GRK2, CLK2 | LRRK2 1/4885MMP2 4509/4885ADAMTS5 4839/4885 |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, GRK2, CLK2 | LRRK2 1/4885MMP2 4509/4885ADAMTS5 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.